Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.76 |
| ▸ | EP300 | Q09472 | 2/20 | 0.73 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30881664 | 1.00 | IDO1 (0.76) | IDO1EP300KAT8ALDH1A1TDP1 | |
| SCHEMBL331453 | 0.86 | IDO1 (1.00) | IDO1EP300KAT8ALDH1A1TDP1 | |
| SCHEMBL31116611 | 0.85 | CA1 (0.61) | IDO1EP300KAT8ALDH1A1TDP1 | |
| SCHEMBL357145 | 0.85 | CA1 (0.61) | IDO1EP300KAT8ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL6155452 | 0.84 | EP300 (1.00) | IDO1EP300KAT8ALDH1A1TDP1 | |
| SCHEMBL11674477 | 0.81 | IDO1 (0.62) | IDO1EP300KAT8ALDH1A1TDP1 | |
| SCHEMBL12473426 | 0.80 | CA1 (0.55) | IDO1EP300KAT8ALDH1A1TDP1 | |
| SCHEMBL5749415 | 0.79 | NQO1 (0.53) | IDO1EP300KAT8ALDH1A1TDP1 | |
| SCHEMBL11618652 | 0.78 | IDO1 (0.64) | IDO1EP300KAT8ALDH1A1TDP1 | |
| SCHEMBL5747064 | 0.78 | ALDH1A1 (0.50) | IDO1EP300KAT8ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024099269-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, USE THEREOF | 华东师范大学 | 2024-05-16 | — | — | WO | disclosed |
| CN-118026880-A | Aryl amide compound, pharmaceutical composition containing same and application thereof | 华东师范大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-106380408-A | Preparation of optical homochiral amine | 王际菊 | 2017-02-08 | — | — | CN | disclosed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20130286338-A1 | Liquid Crystal Display Device and Method of Fabricating the Same | LG DISPLAY CO LTD (KR) | 2013-10-31 | — | — | US | disclosed |
| US-20130286338-A1 | Liquid Crystal Display Device and Method of Fabricating the Same | LG DISPLAY CO LTD (KR) | 2013-10-31 | — | — | US | disclosed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| EP-1659117-A1 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20050267152-A1 | Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders | MDS INC., DOING BUSINESS AS MDS SCIEX (CA) | 2005-12-01 | — | — | US | disclosed |
| WO-2005049023-A1 | GLYT1 TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| EP-1455777-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003055478-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-10 | — | — | WO | disclosed |
| WO-2001010890-A2 | PROCESS OF SYNTHESIS OF FLUORESCENT PROTEASE SUBSTRATES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| EP-0148201-A4 | NAPHTALENE AMINOALKYLENE ETHERS AND THIOETHERS, AND THEIR PHARMA CEUTICAL USES. | RORER INTERNAT OVERSEAS INC (US) | 1985-09-26 | — | — | EP | disclosed |
| US-4543352-A | ANTISECRETORY, ANTIULCER, ANTACID, HISTAMINE H2-ANTAGONISTS | WILLIAM H. RORER, INC. (US) | 1985-09-24 | — | — | US | disclosed |
| EP-0148201-A1 | NAPHTALENE AMINOALKYLENE ETHERS AND THIOETHERS, AND THEIR PHARMA CEUTICAL USES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1985-07-17 | — | — | EP | disclosed |
| WO-1984004245-A1 | NAPHTALENE AMINOALKYLENE ETHERS AND THIOETHERS, AND THEIR PHARMA CEUTICAL USES | RORER INT OVERSEAS (US) | 1984-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | IDO1 1625/4885EP300 1670/4885KAT8 3183/4885 |
| US-20050267152-A1 | Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders | SLC1A2, SLC1A1, SLC18A2 | IDO1 548/4885EP300 3516/4885KAT8 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.